Diverse therapeutics, including monoclonal antibodies to CD47 or SIRPα, receptor decoys, and bispecific antibodies that block the CD47-SIRPα axis have demonstrated significant anti-tumor activity in preclinical models of various hematological neoplasms [30, 31]. The gene discussed is SIRPA; the disease is neoplasm.